LabRoots and the Drug Discovery planning committee are pleased to announce the 5th Annual Drug Discovery & Development Virtual Conference. Labroots will host this online-only event on February 23, 2022. The Drug Discovery planning committee will invite speakers from industry and academia to discuss key challenges, new opportunities, and recent successes in the current landscape of drug discovery and development.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2022 Drug Discovery & Development Virtual Event. Submission is free. Submit your abstract here.
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global drug discovery community with a high degree of interaction through live-streaming video and chat sessions.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Use #LRdrug to follow the conversation!
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
An Associate Professor with Midwestern University, Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she ...See more See less
Matt entered the research field over 20 years ago as a lab animal technician at the TSI/Mason contract research facility. He has worked at both contract facilities such as TSI and OREAD Biosafety as well in industry at Pharmacia, Pfizer, and Sanofi-Aventis. During that period he ...See more See less
Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...See more See less
Over the past 16 years, Mr. Shipton has amassed deep domain expertise in cell-based products and services. Currently serving as President of Novabiosis, Inc. Mr. Shipton brings a skill for implementing sales-driven business strategies, an extensive track record of meeting and ...See more See less
Professor Pfleger is Director, Biomedical Innovation at The University of Western Australia (UWA) and the MTPConnect Western Australian Life Sciences Innovation Hub. He is also Head of Molecular Endocrinology and Pharmacology at the UWA Centre for Medical Research and Harry ...See more See less